Nurix Therapeutics, Inc. (NRIX) Stock Analysis and Metrics

Nurix Therapeutics

NASDAQ: NRIX

$23.40 ▼ -0.34 (-1.43%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.60 Bn

P/E-7.60

P/S70.70

Div. Yield0.00

Revenue Growth (1y) (Qtr)-79.47

Add ratio to table…

About

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines for the treatment of cancer and inflammatory diseases. The company leverages its fully artificial intelligence-integrated discovery engine, DEL-AI, combined with leading ligase expertise, to design and advance degrader-based therapeutics that aim to remove disease-causing proteins from cells. Nurix's pipeline includes wholly owned clinical stage drug candidates such as bexobrutideg, a selective degrader of Bruton's tyrosine kinase (BTK); zelebrudomide, a dual degrader of BTK and the transcription factors IKZF1 and IKZF3; and NX-1607, an inhibitor of the E3 ligase CBL-B. The company also advances preclinical programs and maintains collaboration agreements with Gilead Sciences, Sanofi, and Pfizer to expand its therapeutic reach into additional indications including rheumatoid arthritis, Type 2 inflammation, and solid tumors.

Nurix Therapeutics generates revenue through upfront payments, research milestone payments, license option exercise fees, research term extension payments, and potential future milestone and royalty payments from its collaboration agreements with Gilead, Sanofi, and Pfizer. As of November 30, 2025, the company has received a total of $482.0 million in non-dilutive financing from these collaborators. Under these agreements, Nurix retains responsibility for preclinical research activities while partners handle clinical development, commercialization, and manufacturing, with Nurix maintaining options for co-development, co-promotion, and profit sharing in the United States for certain drug candidates. The company does not currently generate revenue from product sales as all drug candidates remain in clinical or preclinical development.

The company operates through the following segments: Targeted Protein Degradation and Degrader Antibody Conjugates.

• The Targeted Protein Degradation segment encompasses the discovery and development of small molecule degrader drugs that harness the ubiquitin proteasome system to eliminate disease-associated proteins. This segment includes Nurix's wholly owned clinical programs targeting BTK (bexobrutideg and zelebrudomide) and CBL-B (NX-1607), as well as preclinical programs such as the pan-mutant BRAF degrader initiative and collaborations with Gilead and Sanofi targeting IRAK4 and STAT6 for inflammatory conditions and oncology indications.

• The Degrader Antibody Conjugate (DAC) segment focuses on combining targeted protein degrader payloads with monoclonal antibodies to create cell- and tissue-specific therapies. This segment leverages Nurix's DEL-AI platform and degrader expertise in partnership with Pfizer, which provides antibody conjugate design and development capabilities, to advance DACs for oncology and potential non-oncology indications. Activities include identifying suitable degrader-antibody pairs, optimizing linker chemistry, and advancing candidates through preclinical and clinical development under the Pfizer collaboration agreement.

Nurix Therapeutics holds a competitive advantage in the targeted protein degradation space due to its proprietary DEL-AI discovery engine, which integrates DNA-encoded library screening with machine learning to rapidly identify binders for historically undruggable targets. The company's deep expertise in E3 ligase biology enables it to design degraders with catalytic activity that can eliminate thousands of protein copies per molecule, offering potential advantages over traditional inhibitors in overcoming resistance mutations and addressing scaffolding functions of target proteins. While facing competition from other companies developing BTK degraders and CBL-B inhibitors, Nurix differentiates itself through its integrated AI-driven platform, broad ligandase knowledge, and diversified pipeline across monotherapy and DAC modalities.

Nurix Therapeutics serves patients with cancer, inflammatory diseases, and autoimmune disorders through its therapeutic development efforts. The company's clinical programs focus on relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma, as well as solid tumor indications for its CBL-B inhibitor NX-1607. Through its collaborations, Nurix contributes to the development of treatments for rheumatoid arthritis, Type 2 inflammation, and additional oncology indications, with the ultimate goal of delivering approved medicines to hospitals, clinics, and patients via healthcare providers and pharmacies upon regulatory approval.

Investment Thesis

▲ Bull case

The exclusive licensing and collaboration agreement with Roche worth up to $2.3 billion represents a transformative validation of Nurix Therapeutics' targeted protein degradation platform, particularly for bexobrutideg in chronic lymphocytic leukaemia. This deal provides substantial non-dilutive funding through upfront payments, milestone triggers, and tiered royalties, which significantly de-risks the company's near-term cash runway and allows it to advance multiple preclinical and early-stage programs without relying heavily on dilutive equity financing. The scale of the potential milestone payments indicates Roche's high confidence in bexobrutideg's clinical and commercial potential, suggesting that the drug may possess differentiated efficacy or safety advantages over existing BTK inhibitors in the market, especially in high-unmet-need patient populations. Furthermore, the exclusivity of the agreement prevents competitors from accessing similar Roche resources for comparable targets, reinforcing Nurix's strategic positioning in the oncology degradation space and creating a barrier to entry for rivals pursuing parallel mechanisms.
The planned Phase III trial initiation for bexobrutideg in chronic lymphocytic leukaemia this summer acts as a near-term catalyst that the market may be underestimating, particularly given the drug's mechanism of action as a targeted protein degrader rather than a traditional inhibitor. Unlike reversible BTK inhibitors that can lead to resistance via mutations like C481S, bexobrutideg's ability to completely eliminate the BTK protein may overcome common resistance pathways, potentially yielding deeper and more durable responses in patients who have progressed on prior therapies. This mechanistic advantage could translate into superior progression-free and overall survival rates in the Phase III setting, positioning bexobrutideg as a potential best-in-class or even first-in-class option for specific CLL subsets, especially in relapsed/refractory or high-risk genetic profiles. Success in this trial would not only unlock substantial milestone payments under the Roche deal but also establish a clinical foundation for expanding bexobrutideg into earlier lines of therapy and other B-cell malignancies, thereby expanding its addressable market well beyond the initial indication.
Nurix Therapeutics' broader pipeline of targeted protein degraders, particularly those leveraging its DELigase® platform for E3 ligase modulation, remains underappreciated by investors focused solely on the Roche collaboration. The company has multiple preclinical and IND-enabling programs in oncology and immunology that target traditionally "undruggable" proteins, with early data suggesting favorable pharmacokinetic profiles and tissue selectivity that could mitigate historical challenges associated with degrader therapeutics, such as off-target effects or hook effect limitations. The Roche partnership not only validates the core technology but also provides Nurix with access to Roche's extensive clinical development infrastructure, regulatory expertise, and global commercialization capabilities, which can be leveraged across its own pipeline through potential future collaborations or internal advancement. This creates a compounding effect where success with bexobrutideg de-risks the platform, making it easier to attract additional partners for other targets and accelerating the valuation inflection point for the company's entire pipeline.

The exclusive licensing and collaboration agreement with Roche worth up to $2.3 billion represents a transformative validation of Nurix Therapeutics' targeted protein degradation platform, particularly for bexobrutideg in chronic lymphocytic leukaemia. This deal provides substantial non-dilutive funding through upfront payments, milestone triggers, and tiered royalties, which significantly de-risks the company's near-term cash runway and allows it to advance multiple preclinical and early-stage programs without relying heavily on dilutive equity financing. The scale of the potential milestone payments indicates Roche's high confidence in bexobrutideg's clinical and commercial potential, suggesting that the drug may possess differentiated efficacy or safety advantages over existing BTK inhibitors in the market, especially in high-unmet-need patient populations. Furthermore, the exclusivity of the agreement prevents competitors from accessing similar Roche resources for comparable targets, reinforcing Nurix's strategic positioning in the oncology degradation space and creating a barrier to entry for rivals pursuing parallel mechanisms.
The planned Phase III trial initiation for bexobrutideg in chronic lymphocytic leukaemia this summer acts as a near-term catalyst that the market may be underestimating, particularly given the drug's mechanism of action as a targeted protein degrader rather than a traditional inhibitor. Unlike reversible BTK inhibitors that can lead to resistance via mutations like C481S, bexobrutideg's ability to completely eliminate the BTK protein may overcome common resistance pathways, potentially yielding deeper and more durable responses in patients who have progressed on prior therapies. This mechanistic advantage could translate into superior progression-free and overall survival rates in the Phase III setting, positioning bexobrutideg as a potential best-in-class or even first-in-class option for specific CLL subsets, especially in relapsed/refractory or high-risk genetic profiles. Success in this trial would not only unlock substantial milestone payments under the Roche deal but also establish a clinical foundation for expanding bexobrutideg into earlier lines of therapy and other B-cell malignancies, thereby expanding its addressable market well beyond the initial indication.
Nurix Therapeutics' broader pipeline of targeted protein degraders, particularly those leveraging its DELigase® platform for E3 ligase modulation, remains underappreciated by investors focused solely on the Roche collaboration. The company has multiple preclinical and IND-enabling programs in oncology and immunology that target traditionally "undruggable" proteins, with early data suggesting favorable pharmacokinetic profiles and tissue selectivity that could mitigate historical challenges associated with degrader therapeutics, such as off-target effects or hook effect limitations. The Roche partnership not only validates the core technology but also provides Nurix with access to Roche's extensive clinical development infrastructure, regulatory expertise, and global commercialization capabilities, which can be leveraged across its own pipeline through potential future collaborations or internal advancement. This creates a compounding effect where success with bexobrutideg de-risks the platform, making it easier to attract additional partners for other targets and accelerating the valuation inflection point for the company's entire pipeline.

▼ Bear case

Despite the headline value of the Roche deal being up to $2.3 billion, a significant portion of this potential is contingent on successfully achieving stringent clinical, regulatory, and commercial milestones, many of which are tied to Phase III success, regulatory approval, and sales thresholds in competitive markets. The upfront payment and near-term milestones are likely insufficient to fully fund Nurix's operations through multiple readouts, meaning the company may still face funding gaps that necessitate future dilutive financings if bexobrutideg encounters delays or setbacks in its Phase III trial for chronic lymphocytic leukaemia. Moreover, the tiered royalty structure implies that Nurix will only receive a modest percentage of net sales even if the drug is commercialized, limiting long-term upside participation compared to retaining full rights, and suggesting that the market may be overestimating the sustainable profitability impact of this partnership on Nurix's standalone financial profile.
The initiation of the Phase III trial for bexobrutideg in chronic lymphocytic leukaemia this summer, while promising, carries substantial clinical risk given the crowded and rapidly evolving BTK inhibitor landscape, where next-generation covalent and non-covalent inhibitors are already demonstrating strong efficacy and safety profiles in relapsed/refractory settings. Bexobrutideg's degrader mechanism, although theoretically advantageous, introduces novel uncertainties related to protein degradation efficiency, potential off-target degradation of structurally similar proteins, and the long-term consequences of sustained BTK depletion, which could impair immune function or lead to unforeseen toxicities not seen with inhibitory approaches. Additionally, chronic lymphocytic leukaemia patients often have complex comorbidities and are frequently elderly, increasing susceptibility to adverse events that could halt or delay trial readouts, especially if the drug demonstrates any signal of hematological toxicity, infection risk, or cardiovascular effects during prolonged dosing.
Nurix Therapeutics remains heavily dependent on the success of a single asset—bexobrutideg—within its collaboration with Roche, creating significant concentration risk, as the company's near-term valuation and investor sentiment are disproportionately tied to one clinical readout. While the DELigase® platform is promising, most of Nurix's other programs are still in preclinical stages, with limited public data on target engagement, efficacy in vivo, or developability, making it difficult to assess whether the platform can consistently generate viable drug candidates beyond bexobrutideg. Furthermore, the competitive landscape in targeted protein degradation is intensifying, with multiple well-funded peers advancing similar E3 ligase-modulating technologies, increasing the risk that Nurix could lose its technological edge or face challenges in securing additional partnerships if early results from its internal pipeline fail to impress. Without near-term diversification of value inflection points, the company's stock may exhibit heightened volatility around binary events related to bexobrutideg, with limited buffer against downside should the Phase III trial fail to meet its primary endpoints.

Despite the headline value of the Roche deal being up to $2.3 billion, a significant portion of this potential is contingent on successfully achieving stringent clinical, regulatory, and commercial milestones, many of which are tied to Phase III success, regulatory approval, and sales thresholds in competitive markets. The upfront payment and near-term milestones are likely insufficient to fully fund Nurix's operations through multiple readouts, meaning the company may still face funding gaps that necessitate future dilutive financings if bexobrutideg encounters delays or setbacks in its Phase III trial for chronic lymphocytic leukaemia. Moreover, the tiered royalty structure implies that Nurix will only receive a modest percentage of net sales even if the drug is commercialized, limiting long-term upside participation compared to retaining full rights, and suggesting that the market may be overestimating the sustainable profitability impact of this partnership on Nurix's standalone financial profile.
The initiation of the Phase III trial for bexobrutideg in chronic lymphocytic leukaemia this summer, while promising, carries substantial clinical risk given the crowded and rapidly evolving BTK inhibitor landscape, where next-generation covalent and non-covalent inhibitors are already demonstrating strong efficacy and safety profiles in relapsed/refractory settings. Bexobrutideg's degrader mechanism, although theoretically advantageous, introduces novel uncertainties related to protein degradation efficiency, potential off-target degradation of structurally similar proteins, and the long-term consequences of sustained BTK depletion, which could impair immune function or lead to unforeseen toxicities not seen with inhibitory approaches. Additionally, chronic lymphocytic leukaemia patients often have complex comorbidities and are frequently elderly, increasing susceptibility to adverse events that could halt or delay trial readouts, especially if the drug demonstrates any signal of hematological toxicity, infection risk, or cardiovascular effects during prolonged dosing.
Nurix Therapeutics remains heavily dependent on the success of a single asset—bexobrutideg—within its collaboration with Roche, creating significant concentration risk, as the company's near-term valuation and investor sentiment are disproportionately tied to one clinical readout. While the DELigase® platform is promising, most of Nurix's other programs are still in preclinical stages, with limited public data on target engagement, efficacy in vivo, or developability, making it difficult to assess whether the platform can consistently generate viable drug candidates beyond bexobrutideg. Furthermore, the competitive landscape in targeted protein degradation is intensifying, with multiple well-funded peers advancing similar E3 ligase-modulating technologies, increasing the risk that Nurix could lose its technological edge or face challenges in securing additional partnerships if early results from its internal pipeline fail to impress. Without near-term diversification of value inflection points, the company's stock may exhibit heightened volatility around binary events related to bexobrutideg, with limited buffer against downside should the Phase III trial fail to meet its primary endpoints.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password